BioNexus Gene Lab Corp.(BGLC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BGLC BioNexus Gene Lab Corp.

Trading 01-22 12:27:31 EST

3.12

-0.01

-0.32%

High3.12	Low3.02	Vol4.46K
Open3.02	D1 Closing3.13	Amplitude3.19%
Mkt Cap7.38M	Tradable Cap5.30M	Total Shares2.36M
T/O13.60K	T/O Rate0.26%	Tradable Shares1.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BGLC","market":"US","secType":"STK","nameCN":"BioNexus Gene Lab Corp.","latestPrice":3.12,"timestamp":1769102335890,"preClose":3.13,"halted":0,"volume":4463,"delay":0,"changeRate":-0.0031948881789136702,"floatShares":1700000,"shares":2363800,"eps":-1.278333,"marketStatus":"Trading","change":-0.01,"latestTime":"01-22 12:27:31 EST","open":3.02,"high":3.12,"low":3.02,"amount":13599.0033409,"amplitude":0.031949,"askPrice":3.45,"askSize":333,"bidPrice":3.17,"bidSize":131,"shortable":0,"etf":0,"ttmEps":-1.278333,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769115600000},"marketStatusCode":2,"adr":0,"listingDate":1689825600000,"exchange":"NASDAQ","adjPreClose":3.13,"preHourTrading":{"tag":"盘前","latestPrice":3.07,"preClose":3.13,"latestTime":"09:29 EST","volume":172,"amount":525.3000056000001,"timestamp":1769092199032,"change":-0.06,"changeRate":-0.019169,"amplitude":0.015974},"postHourTrading":{"tag":"盘后","latestPrice":3.07,"preClose":3.067,"latestTime":"19:46 EST","volume":401,"amount":1234.35,"timestamp":1769042770877,"change":0.003,"changeRate":0.000978,"amplitude":0.007499},"volumeRatio":0.924977},"requestUrl":"/m/hq/s/BGLC/tweets","defaultTab":"tweets","newsList":[{"id":"2593268446","title":"BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593268446","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593268446?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:55","pubTimestamp":1766530509,"startTime":"0","endTime":"0","summary":"BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC FilingDec 23  - BioNexus Gene Lab Corp BGLC.O:BIONEXUS GENE LAB CORP - MATTHEW L. BARSING APPOINTED AS CHAIRMAN OF CHEMREX BOARD - SEC FILINGSource text: [ID:n0001477932-25-009186]Further company coverage: BGLC.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2593446589","title":"BioNexus Gene Lab Corp - Matthew L. Barsing Appointed as Chairman of Chemrex Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446589?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:32","pubTimestamp":1766529147,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2593450004","title":"Chemrex Board Reshuffled Amid Governance Review at BioNexus Gene Lab Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2593450004","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593450004?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:21","pubTimestamp":1766528476,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. Appoints New Chairman and Reconstitutes Chemrex Board Amid Governance Review. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL13jgcW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2588047603","title":"Correction: Blue Gold Sets $15 Million Gold Trading Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2588047603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588047603?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:01","pubTimestamp":1764774076,"startTime":"0","endTime":"0","summary":"Blue Gold  said Wednesday that it has expanded its partnership with DL Hudson Dunes to add a $15 million facility to finance gold trades.The facility will fund purchases of gold from mines and licensed aggregators worldwide, with a target of two to three trades a month and projected profit margins of 1% to 5% per trade, the company said.DL Hudson Dunes will partner on each transaction to provide legal, compliance and commercial support for the trading operations, Blue Gold said.The company said it ultimately plans to move further into mining in West Africa and Latin America and to launch a fintech wallet and payment card by Q3, 2026, to support spending of its Standard Gold Coin.Shares of the company were up more than 1% in recent early trading on Wednesday.Price: 4.55, Change: -0.02, Percent Change: -0.44","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGL","BK7104","BK4104","BGL.AU","BGLC","BK4017"],"gpt_icon":0},{"id":"2588044606","title":"Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044606?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:09","pubTimestamp":1764770978,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - BioNexus Gene Lab Corp ::*BIONEXUS GENE LAB CORP. COMPLETES STRATEGIC INVESTMENT IN FIDELION DIAGNOSTICS; SECURES 15% EQUITY STAKE IN GLOBAL AI-ONCOLOGY PLATFORM AND EXCLUSIVE SOUTHE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nRSD3NbFjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2588041193","title":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041193","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041193?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769516,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard Tumor-Nave Minimal Residual Disease  liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL3sWBGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","BK4104","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BGLC","LU0314104364.USD"],"gpt_icon":0},{"id":"2588188041","title":"BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for Vitaguard™","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA1RP08D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588605376","title":"BioNexus Gene Lab Corp - Enters $500 Mln Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588605376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588605376?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588053088","title":"BioNexus Gene Lab Corp - May Issue Shares to ARC Group International Over 36 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053088?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80NA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2588011053","title":"BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011053","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011053?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680700,"startTime":"0","endTime":"0","summary":"SHERIDAN, Wyo., Dec.  02, 2025  (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197900/0/en/BioNexus-Gene-Lab-Corp-Nasdaq-BGLC-Secures-500-Million-Equity-Facility-From-ARC-Group-International-to-Support-Expansion-of-Precision-Diagnostics-CDMO-Operations-and-Therapeutic-Co.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","EQR","BGLC","BK4104","BK4139","ARC","BK4588","BK4585","BK4143","BK4215"],"gpt_icon":0},{"id":"2588977806","title":"BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion","url":"https://stock-news.laohu8.com/highlight/detail?id=2588977806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588977806?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:50","pubTimestamp":1764597034,"startTime":"0","endTime":"0","summary":"BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To FidelionDec 1 (Reuters) - BioNexus Gene Lab Corp BGLC.O:BIONEXUS GENE LAB CORP - TO PAY $2 MILLION LICENSE FEE TO FIDELIONSource text: ID:nGNX67xlVYFurther company coverage: BGLC.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2588720631","title":"BioNexus Gene Lab Corp - to Pay $2 Mln License Fee to Fidelion","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720631?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:04","pubTimestamp":1764594245,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2588720879","title":"BioNexus Gene Lab Secures Exclusive Southeast Asia License for VitaGuard MRD Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720879","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720879?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594030,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. has announced the execution of an Exclusive Intellectual Property License Agreement with Fidelion Diagnostics Pte. Ltd. for the VitaGuard minimal residual disease  liquid biopsy platform in Southeast Asia. The agreement grants BioNexus Gene Lab Corp. exclusive, perpetual rights to the VitaGuard MRD platform across the region. This license is a key condition for the completion of a previously announced Share Subscription and Shareholders' Agreement among BioNexus Gene Lab Corp., Fidelion Diagnostics, and Tongshu Gene, under which BioNexus Gene Lab Corp. will become a strategic shareholder in Fidelion Diagnostics, with Fidelion Diagnostics taking a minority stake in BioNexus Gene Lab Corp.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4KsN2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","BK4588","NDAQ","IE00B64PRP62.GBP","BGLC","BK4585","BK4104","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584921884","title":"Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921884","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921884?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:07","pubTimestamp":1763572056,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp ::*BIONEXUS GENE LAB CORP FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-NOV-202522:15:55 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbXvkVv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2583684259","title":"BioNexus Gene Lab Corp. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684259","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684259?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:30","pubTimestamp":1763155856,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp. will hold its Annual Meeting of Stockholders online on December 24, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9pdyV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2582737480","title":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582737480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582737480?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:32","pubTimestamp":1762954366,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp.  has entered into definitive agreements involving an equity investment with Fidelion Diagnostics Pte. Ltd. As part of the deal, BGLC will receive new shares representing at least 15% of Fidelion's fully diluted share capital. In exchange, Fidelion will receive newly issued, restricted shares equal to 19.9% of BGLC's pre-money outstanding shares. This cross-equity alignment is part of a broader collaboration to commercialize VitaGuard, a next-generation liquid-biopsy platform for minimal residual disease  testing across Southeast Asia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9W9Qn9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2582379236","title":"BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379236?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952437,"startTime":"0","endTime":"0","summary":"BioNexus Gene Lab Corp.  announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology  Co., Limited to commercialize VitaGuard, a tumor-nave liquid-biopsy platform for minimal residual disease  detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL83YHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","BK4112","BGLC","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2582797853","title":"BioNexus Gene Lab Corp: Completion Is Conditioned on an Ip License Agreement Granting Bglc Exclusive Commercialization Rights Across Asean","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797853?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6S22QG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BGLC","BK4104"],"gpt_icon":0},{"id":"2582379203","title":"BioNexus Gene Lab Corp - to Receive 15% of Fidelion Shares; Fidelion Will Receive 19.9% of Bglc's Pre-Money Outstanding Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379203?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6S22QG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0},{"id":"2582115379","title":"BioNexus Gene Lab Corp. (Nasdaq: Bglc) Announces Strategic Agreements With Fidelion Diagnostics for Southeast Asia Mrd Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2582115379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582115379?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6S22QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BGLC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bionexusgenelab.com","stockEarnings":[{"period":"1week","weight":-0.1843},{"period":"1month","weight":-0.252},{"period":"3month","weight":-0.4091},{"period":"6month","weight":-0.3741},{"period":"1year","weight":-0.1709},{"period":"ytd","weight":-0.2235}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.010544},{"month":2,"riseRate":0.4,"avgChangeRate":-0.079222},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0169},{"month":4,"riseRate":0.2,"avgChangeRate":-0.080248},{"month":5,"riseRate":0.2,"avgChangeRate":-0.121009},{"month":6,"riseRate":0.2,"avgChangeRate":-0.096252},{"month":7,"riseRate":0.6,"avgChangeRate":0.191553},{"month":8,"riseRate":0.4,"avgChangeRate":0.000036},{"month":9,"riseRate":0.2,"avgChangeRate":-0.161516},{"month":10,"riseRate":0.333333,"avgChangeRate":0.085347},{"month":11,"riseRate":0.5,"avgChangeRate":0.129387},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.061457}],"exchange":"NASDAQ","name":"BioNexus Gene Lab Corp.","nameEN":"BioNexus Gene Lab Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNexus Gene Lab Corp.(BGLC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioNexus Gene Lab Corp.(BGLC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioNexus Gene Lab Corp.,BGLC,BioNexus Gene Lab Corp.股票,BioNexus Gene Lab Corp.股票老虎,BioNexus Gene Lab Corp.股票老虎国际,BioNexus Gene Lab Corp.行情,BioNexus Gene Lab Corp.股票行情,BioNexus Gene Lab Corp.股价,BioNexus Gene Lab Corp.股市,BioNexus Gene Lab Corp.股票价格,BioNexus Gene Lab Corp.股票交易,BioNexus Gene Lab Corp.股票购买,BioNexus Gene Lab Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNexus Gene Lab Corp.(BGLC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioNexus Gene Lab Corp.(BGLC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction